BUZZ-Lumexa shares rise after Truist gives "Buy" rating
路透社2026/10/05 12:21On October 5th, shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading to $10.6. Brokerage Truist Securities initiated coverage with a “Buy” rating and a target price of $18, which implies about 74% upside from the previous trading day’s close. The company offers diagnostic imaging services, including MRI, CT, and PET scans, as well as X-ray, ultrasound, and mammography services. All five brokerages currently covering LMRI have assigned it a “Buy” or higher rating, with a median target price of $17.50, according to data compiled by LSEG. As of the previous close, LMRI’s share price has declined 44.22% year-to-date. (For non-English speakers, Reuters automatically translates its reports into several languages. Due to the possibility of errors or missing context in automated translations, Reuters does not guarantee their accuracy and provides these translations solely for reader convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation.)
October 5 - ** Shares of diagnostic equipment supplier Lumexa Imaging (LMRI.O) rose 2% in pre-market trading, at $10.6.
** Brokerage Truist Securities initiated coverage (link), with a "Buy" rating and a target price of $18.
** This target price suggests an upside of about 74% compared to the previous trading day's closing price.
** The company offers diagnostic imaging services, including MRI, CT and PET scans, as well as X-ray, ultrasound and mammography services.
** All 5 brokerages currently covering this stock rate LMRI as "Buy" or above; their median target price is $17.50 — LSEG compiled data.
** As of the previous trading day’s close, LMRI shares had fallen 44.22% year-to-date.
(To assist non-native English speakers, Reuters has automatically translated its report into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation and provides it solely for readers’ convenience. Reuters accepts no liability for any damage or loss arising from the use of automated translation features.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Indonesian Rupiah: Limited relief, challenging backdrop – OCBC
Buying Wind in the Cryptocurrency Market! Significant Activity in Bitcoin, Ethereum, and Solana! Here are the Details…
Hulamin says Paul Baloyi resigns as independent non-executive director
Hulamin said independent non-executive director Paul Baloyi resigned, effective Oct. 2, 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hulamin Ltd. published the original content used to generate this news brief via SENS, the regulatory disclosure system operated by the Johannesburg Securities Exchange (JSE) (Ref. ID: S604350), on October 05, 2026, and is solely responsible for the information contained therein.
US Stock Move | Pneumococcal vaccine achieves late-stage clinical trial target, Vaxcyte (PCVX.US) opens more than 50% higher
On Monday, Vaxcyte (PCVX.US) soared more than 50% at the open and was up approximately 53% at the time of writing, with a market capitalization of 12.8 billions USD.
Crypto prices
More
